We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

Biopharmaceutical company Sutro Biopharma successfully listed on the NASDAQ via IPO, surging more than 73% on its first day of trading

Biopharmaceutical company Sutro Biopharma successfully listed on the NASDAQ via IPO, surging more than 73% on its first day of trading

February 3, 2023, Structure Therapeutics(Structure Therapeutics Inc., formerly known as ShouTi Inc.) listed on the NASDAQ in the United States, issuing 10.74 million ADS shares at an offering price of $15.00 per ADS, raising $161.1 million.

In addition, Structure Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1.611 million ADS shares at the initial public offering price. Structure Therapeutics’ stock ticker is “GPCR”.

Structure Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel oral small molecule therapies for metabolic and pulmonary diseases. Currently, the company focuses on the development of G protein-coupled receptor (GPCR)-targeted therapies, with two pipeline candidates having entered clinical development.

Jefferies, SVB Securities, Guggenheim Securities and BMO Capital Markets served as joint bookrunners for this offering.

Structure Therapeuticswas co-founded by Dr. Raymond Stevens and Rich Friesner, founder of Schrodinger, a well-known AI pharmaceutical public company. It is a biotech company that utilizes structure-based drug design technology, combined with advanced computing and world-class expertise, to translate biologics and peptide drugs into oral small molecule drugs with excellent efficacy. The company focuses on the development of G protein-coupled receptor (GPCR)-targeted therapies, with two pipeline candidates having entered clinical development.

Prior to the IPO, Structure Therapeutics’ shareholders included Sequoia China (10.30%), BVF Partners (9.56%), Fidelity Management & Research Company (8.35%), Hillhouse Capital (8.06%), F-Prime Capital (7.5%), Qiming Venture Partners (6.37%), Deep Track Capital (6.37%); in addition, Structure Therapeutics’ investors also included WuXi AppTec, Lilly Asia Ventures, and Takeda Ventures, among others.

As of the close of trading on February 3, Structure Therapeuticsclosed at $26 per share, surging 73.33%, with a total market capitalization of approximately $905 million.

According to Structure Therapeutics’ prospectus, GPCRs regulate a wide range of physiological and pathological processes, with approximately one in three approved drugs targeting GPCR-related pathways, already delivering innovative therapies to millions of patients with conditions including diabetes, bipolar disorder, asthma, hypertension and cardiovascular disease. However, the development of innovative drugs targeting these therapies still faces numerous challenges, including: 1) low expression levels on cell surfaces; 2) the complexity of multi-subunit peptide GPCR receptors; 3) difficulty in obtaining relevant crystal structures as a basis for drug design; 4) non-specific signaling through multiple intracellular pathways that may increase side effects.

To address these challenges, Structure Therapeutics has developed a platform designed to solve these key challenges, enabling the company to discover small molecule drugs that effectively target GPCRs. The company’s drug discovery platform combines advances in computational chemistry, visual molecular interaction and intelligent data integration, aiming to design small molecule drugs with “best-in-class” potential to overcome the current limitations of biologics and peptide drugs. Currently, the company is advancing multiple product programs, focusing on chronic diseases with unmet global needs, including cardiovascular, metabolic and pulmonary diseases, with two small molecule compounds having entered clinical stages.

Among them, GSBR-1290 is an oral small-molecule GLP-1 receptor (GLP-1R) agonist being developed for the treatment of patients with type 2 diabetes and obesity. GLP-1R is a validated drug target for the treatment of diabetes and obesity. Previously, GSBR-1290 completed the Phase 1 single ascending dose study in September 2022. The product was generally well-tolerated and exhibited dose-dependent pharmacokinetic (PK) and pharmacodynamic (PD) activities. Sortino Therapeutics initiated the Phase 1b multiple ascending dose study in January 2023 and expects to launch the Phase 2a proof-of-concept study for type 2 diabetes and obesity in the second half of 2023.

▲ Sortino Therapeutics' pipeline in development (Image source: Sortino Therapeutics' prospectus)

Another drug candidate that has entered the clinical trial stage, ANPA-0073, is a small-molecule product candidate targeting the apelin receptor (APJR), intended for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). In September 2022, Sortino Therapeutics completed the Phase 1 single ascending dose study and multiple ascending dose study for this product, showing that ANPA-0073 was generally well-tolerated in healthy human volunteers.

In addition, Sortino Therapeutics is also developing next-generation GLP-1R candidates, including GLP-1R/GIPR dual agonists, intended for the treatment of patients with type 2 diabetes and obesity; a differentiated lysophosphatidic acid 1 receptor (LPA1R) antagonist, intended for the treatment of idiopathic pulmonary fibrosis.

Public information shows that Sortino Therapeutics announced the completion of a $100 million Series B financing in October 2021; in August 2022, the company completed an oversubscribed financing of $33 million. Sortino Therapeutics' listing on the NASDAQ marks the start of a new journey for the company in the capital market. With the help of capital, we look forward to the accelerated development of the company's products in development, which will help patients worldwide as soon as possible.

Originally published on 金盒企业管理集团